Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
teverelix TFA · 1 trial · 1 indication
Proportion of participants achieving castration level with serum T \<0.5 ng/mL at Day 28.
| Arm | Type | Description |
|---|---|---|
| Teverelix TFA 120 mg 6-weekly | EXPERIMENTAL | Participants receive teverelix TFA loading dose on Day 0 (120 mg SC + 120 mg IM) and teverelix TFA maintenance doses of 120 mg SC at week 6 and 6-weekly thereafter up to week 24 |
| Teverelix TFA 180 mg 6-weekly | EXPERIMENTAL | Participants receive teverelix TFA loading dose on Day 0 (180 mg SC + 180 mg IM) and teverelix TFA maintenance doses of 180 mg SC at week 6 and 6-weekly thereafter up to week 24 |
| Name | Type | Description |
|---|---|---|
| teverelix TFA 120 mg | DRUG | Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24 |
| teverelix TFA 180 mg | DRUG | Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24 |
Inclusion Criteria: * Is male, aged ≤80 years (≥18 years) at the beginning of the treatment period (Day 0) * Has histologically proven advanced adenocarcinoma of the prostate (metastatic or non metastatic hormone-sensitive non curative), suitable for ADT * Is treatment naïve for any of the followin...
Teverelix TFA is being studied for prostatic adenoma, a non-cancerous enlargement of the prostate. It is also known as teverelix TFA 120 mg. The drug is an investigational small molecule in Phase 2 development, and it has been evaluated in a completed Phase 2 trial in adult men with this condition.
Teverelix TFA is being developed by Medicus Pharma Ltd., which trades under the ticker MDCX. The company is responsible for the clinical program evaluating the drug in prostatic adenoma.
Teverelix TFA is in Phase 2 clinical development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA for any indication.
Teverelix TFA has been studied in one completed Phase 2 trial, NCT04693507, titled Teverelix Evaluated in Advanced Prostate Cancer. The trial enrolled 50 male participants aged 18 years and older in Lithuania. It was a controlled study without randomization or double-blinding.